The obesity paradox: association of obesity with improved survival in medically managed severe aortic stenosis

Jinghao Nicholas Ngiam1,* MBBS, MRCP, Nicholas WS Chew2,* MBBS, MRCP, Benjamin Yong-Qiang Tan1 MBBS, MRCP, Hui Wen Sim3 MBBS, MRCP, Ching-Hui Sia2 MBBS, MRCP, William KF Kong2 MBChB, FRACP, Tiong-Cheng Yeo2,3 MBBS, MRCP, Kian-Keong Poh2,3 MBBChir, FACC

1Department of Medicine, National University Health System, 2Department of Cardiology, National University Heart Centre Singapore, National University Health System, 3Yong Loo Lin School of Medicine, National University of Singapore, Singapore
*These authors contributed equally as first authors in this work.

Correspondence: A/Prof Kian-Keong Poh, Senior Consultant, Department of Cardiology, National University Heart Centre Singapore, National University Health System, 1E Kent Ridge Road, NUHS Tower Block, Level 9, Singapore 119228. kian_keong_poh@nuhs.edu.sg

Singapore Med J 2020, 1–16
https://doi.org/10.11622/smedj.2020169
Published ahead of print: 2 December 2020

Online version can be found at
http://www.smj.org.sg/online-first
ABSTRACT

Introduction: The obesity paradox, where obesity is associated with improved survival, has been described in patients undergoing haemodialysis and in heart failure. It was also demonstrated in patients undergoing valve replacement for aortic stenosis (AS). We explored this phenomenon in medically managed severe AS.

Methods: 154 patients with medically managed severe AS (aortic valve area index [AVAi] < 0.6 cm²/m²; mean pressure gradient > 40 mmHg and peak velocity > 400 cm/s) and preserved left ventricular ejection fraction (> 50%) were categorised into the obese (body mass index [BMI] Asian cut-off ≥ 27.5 kg/m²) and non-obese groups. Their clinical and echocardiographic profiles were compared.

Results: 24 (15.6%) patients were obese. Obese patients were similar to non-obese patients in age (68.5 ± 11.6 vs. 68.9 ± 13.1 years) but had higher prevalence of cardiovascular risk factors. Left atrial diameter (43.7 ± 6.7 vs. 38.5 ± 10.2 mm) was larger in obese patients, while left ventricular outflow tract diameter (19.5 ± 1.7 vs. 20.4 ± 2.1 mm) was smaller. Despite lower AVAi in obese patients (0.36 ± 0.10 vs. 0.43 ± 0.11 cm²/m²), there was lower mortality (37.5% vs. 41.0%, log-rank 4.06, p = 0.045) on follow-up (8.0 ± 5.7 years). After adjusting for age and AVA, higher BMI ≥ 27.5 kg/m² remained protective for mortality (hazard ratio 0.38, 95% confidence interval 0.15 to 0.98, p = 0.046).

Conclusion: We demonstrated that obesity was associated with improved survival in severe AS despite lower AVAi and increased prevalence of cardiovascular risk factors.

Keywords: aortic stenosis, clinical outcomes, medical management, obesity paradox
INTRODUCTION

Obesity is a recognised risk factor associated with greater morbidity and mortality.(1) This may be partly explained by the association of obesity with other important medical conditions that are part of the metabolic syndrome, such as hypertension, hyperlipidaemia and diabetes mellitus.(2) The ‘obesity paradox’ refers to a phenomenon where the presence of obesity in certain patient populations may counterintuitively be protective and associated with better survival. This has been consistently described in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting for ischaemic heart disease.(3,4) More recently, the obesity paradox has also been described in other forms of cardiac surgery or intervention, including surgical and transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS).(5-7) The obese patient undergoing cardiac procedures and intervention tended to have better short- and long-term outcomes compared to their non-obese or underweight counterparts.

The rising trend and burden of disease that both obesity and AS pose in the context of a global ageing population highlights the importance of studying this phenomenon.(8) Beyond cardiac surgery, the obesity paradox has also been described in patients with renal failure undergoing haemodialysis and separately, in patients with heart failure.(9,10) For patients with symptomatic severe AS, aortic valve replacement remains the mainstay of therapy, with TAVR being an attractive minimally invasive alternative to surgical valve replacement for moderate-to higher-risk elderly patients.(11,12) It is still unclear if the protective effect of obesity is limited to better periprocedural or surgical outcomes with lower complication rates, or if it also influences the natural history of severe AS. In fact, a previous study had denied the presence of the obesity paradox in patients with severe asymptomatic AS, and showed that obesity was instead associated with increased morbidity and mortality.(13)

Furthermore, a significant proportion of patients with AS, especially in the Asian context, remains medically managed. These patients have either declined intervention for aortic
valve (both transcatheter and surgical) or have been deemed medically unfit for either procedure. The prognosis of these patients would be understandably poorer than for those who undergo valve replacement. However, the impact of obesity on this population with medically managed AS remains unclear. The present study aimed to examine the relationship between obesity (as defined by elevated body mass index [BMI]) and the echocardiographic profiles and clinical outcomes of Asian patients with medically managed severe AS.

METHODS

In this study, 154 consecutive patients with an index echocardiographic diagnosis of severe AS (defined as aortic valve area index [AVAi] < 0.6 cm²/m², transaortic mean pressure gradient > 40 mmHg and transaortic peak velocity > 400 cm/s) were examined from 2000 to 2012. We included only patients with preserved left ventricular ejection fraction (LVEF) > 50% and excluded those with other concomitant valvular pathologies such as significant mitral regurgitation. At the time of the index echocardiography, the anthropomorphic measurements were also obtained, and height and weight were used to compute the BMI. As the study population was Asian, a cut-off BMI of 27.5 kg/m² was used to define the presence of obesity.\(^{(14)}\)

We compared obese and non-obese patients based on differences in the echocardiographic and clinical profiles. The diagnosis and classification of AS, as well as other echocardiographic parameters studied were made in accordance with guidelines of the American Society of Echocardiography/European Association of Cardiovascular Imaging\(^{(15,16)}\).

Subsequently, all 154 patients were followed up prospectively for at least five years after the index echocardiography to evaluate for clinical outcomes in the form of all-cause mortality. These patients were all medically managed, and patients who underwent valve
replacement (transcatheter or surgical) were excluded, as their clinical course would likely have been significantly different. The patients in our study population may have either declined valve replacement or been deemed medically unfit for the procedure. Predicted in-hospital mortality derived from EuroSCORE II was calculated for each patient at the time echocardiography was performed.\(^{(17,18)}\)

Univariate analyses of clinical characteristics and echocardiographic parameters were used to compare the obese and non-obese patients, and these included Student’s \(t\)-tests to examine the association between continuous variables and Pearson’s chi-square test (or Fisher’s exact test where appropriate) to evaluate categorical variables. A multivariable Cox regression model was then constructed to quantify the hazard ratios of parameters associated with all-cause mortality in the study population, adjusting for the effects of older age and aortic valve area on the outcomes. Kaplan-Meier survival curves were constructed to compare differences in survival between the obese and non-obese groups, along with calculation of the log-rank test statistic. A p-value < 0.05 was considered significant. All data analysis was done on IBM SPSS Statistics version 20.0 (IBM Corp, Armonk, NY, USA). This study was approved by the relevant institutional review board prior to its conduct.

RESULTS

Of the 154 patients studied, 24 (15.6%) were obese (BMI \(\geq 27.5\) kg/m\(^2\)), while the remaining 130 (84.4%) patients were non-obese at the time of the index echocardiographic diagnosis of severe AS (AVA\(i\) < 0.6 cm\(^2\)/m\(^2\) and transaortic mean pressure gradient > 40 mmHg and transaortic peak velocity > 400 cm/s). The obese patients were similar in age (68.5 \(\pm\) 11.6 years vs. 68.9 \(\pm\) 13.1 years, \(p = 0.892\)), trended toward a higher prevalence of male gender (66.7\% vs. 50.0\%, \(p = 0.133\)), and had a higher prevalence of cardiovascular risk factors, such as diabetes mellitus (35.0\% vs. 23.8\%, \(p = 0.293\)), hypertension (70.0\% vs. 48.5\%, \(p = 0.079\)) and
hyperlipidaemia (65.0% vs. 33.7%, p = 0.009). There were no significant differences in the prevalence of ischaemic heart disease (20.0% vs. 27.7%, p = 0.474) and chronic kidney disease (10.0% vs. 5.9%, p = 0.504). Predicted in-hospital mortality based on EuroSCORE II was also similar between the two groups (7.3% ± 3.7% vs. 7.9% ± 5.0%, p = 0.706; Table I).

Table I. Univariate analysis comparing obese and non-obese patients in severe aortic stenosis with preserved left ventricular ejection fraction greater than 50%.

| Parameter                          | Obese* (n = 24) | Non-obese* (n = 130) | OR/mean difference (95% CI) | p-value |
|------------------------------------|-----------------|----------------------|-----------------------------|---------|
| Age (yr)                           | 68.5 ± 11.6     | 68.9 ± 13.1          | -0.4 (−6.0 to 5.3)          | 0.892   |
| Body mass index (kg/m²)            | 30.4 ± 2.9      | 21.1 ± 6.8           | 9.3 (6.5 to 12.1)           | < 0.001 |
| Male gender                        | 66.7            | 50.0                 | 1.50 (0.83 to 2.71)         | 0.133   |
| Hypertension                       | 70.0            | 48.5                 | 2.48 (0.88 to 6.96)         | 0.079   |
| Hyperlipidaemia                    | 65.0            | 33.7                 | 3.66 (1.34 to 10.0)         | 0.009   |
| Diabetes mellitus                  | 35.0            | 23.8                 | 1.73 (0.62 to 4.82)         | 0.293   |
| Ischaemic heart disease            | 20.0            | 27.7                 | 0.65 (0.20 to 2.12)         | 0.474   |
| Chronic kidney disease             | 10.0            | 5.9                  | 1.76 (0.33 to 9.42)         | 0.504   |
| Left ventricular ejection fraction (%) | 65.3 ± 8.4     | 67.0 ± 7.5           | −1.6 (−5.0 to 1.7)          | 0.342   |
| Left ventricular mass index (g/m²) | 124.1 ± 34.7    | 134.3 ± 41.3         | −10.2 (−28.3 to 7.9)        | 0.267   |
| Left ventricular internal diameter in diastole (mm) | 47.4 ± 5.9 | 46.0 ± 6.7 | 1.4 (−1.4 to 4.3) | 0.331 |
| Left ventricular interventricular septal diameter in diastole (mm) | 12.3 ± 2.2 | 12.6 ± 2.7 | 0.6 (−1.5 to 0.8) | 0.543 |
| Left ventricular posterior wall diameter in diastole (mm) | 11.7 ± 1.8 | 11.6 ± 1.9 | 0.1 (−0.7 to 0.9) | 0.820 |
| Left atrial diameter (mm)          | 43.7 ± 6.7      | 38.5 ± 10.2          | 5.2 (0.9 to 9.5)            | 0.017   |
| Left ventricular outflow tract diameter (mm) | 19.5 ± 1.7 | 20.4 ± 2.1 | −0.9 (−1.7 to 0.1) | 0.061 |
| Stroke volume index                | 38.4 ± 7.8      | 45.9 ± 11.6          | −7.5 (−12.4 to −2.6)        | 0.003   |
| Low-flow (SVI > 35 mL/m²)          | 33.3            | 29.2                 | 1.21 (0.48 to 3.07)         | 0.687   |
| End-systolic wall stress           | 63.4 ± 15.8     | 57.6 ± 17.3          | 5.8 (−1.7 to 13.3)          | 0.130   |
| Aortic valve area index (cm²/m²)   | 0.36 ± 0.10     | 0.43 ± 0.11          | −0.06 (−0.12 to −0.02)      | 0.006   |
| Transaortic peak velocity (cm/s)   | 474.8 ± 80.9    | 461.6 ± 60.8         | 14.3 (−14.9 to 41.5)        | 0.354   |
| Transaortic mean pressure gradient (mmHg) | 57.6 ± 21.9   | 52.9 ± 15.3          | 4.7 (−2.5 to 11.9)          | 0.200   |
| Predicted in-hospital mortality based on EuroSCORE II (%) | 7.3 ± 3.7 | 7.9 ± 5.0 | −0.6 (−3.9 to 2.7) | 0.706 |
| Mortality                          | 37.5            | 41.0                 | 0.88 (0.51 to 1.54)         | 0.670   |

*Obese = BMI ≥ 27.5 kg/m²; non-obese = BMI < 27.5 kg/m². Data presented as either mean ± standard deviation or percentage. CI: confidence interval; OR: odds ratio; SVI: stroke volume index

In terms of echocardiographic profile, LVEF was preserved in both groups, and not significantly different. Left ventricular (LV) mass index was similar between the two groups (124.1 ± 34.7 g/m² vs. 134.3 ± 41.3 g/m², p = 0.267), with similar thickness of the LV wall but
slightly larger LV internal diameter for obese patients. The left atrial diameter was slightly larger in obese patients (43.7 ± 6.7 mm vs. 38.5 ± 10.2 mm, p = 0.017), but the LV outflow tract diameter (19.5 ± 1.7 vs. 20.4 ± 2.1 mm, p = 0.061) and stroke volume index (38.4 ± 0.7 mL/m² vs. 45.9 ± 11.6 mL/m², p = 0.003) were smaller compared to the non-obese group. In terms of AS severity, it appeared that obese patients had lower AVAi (0.36 ± 0.10 cm²/m² vs. 0.43 ± 0.11 cm²/m², p = 0.006), but there were no significant differences in the transaortic mean pressure gradient or transaortic peak velocity between the groups (Table I).

On subsequent prospective follow-up (mean 8.0 ± 5.7 years), mortality was lower in the obese group (37.5% vs. 41.0%). Constructed Kaplan-Meier survival curves showed improved survival in the obese group compared to the non-obese group (Fig. 1, log-rank test statistic 4.06, p = 0.045). After adjusting for older age and aortic valve area, increased BMI ≥ 27.5 kg/m² remained an independent protective factor for mortality in this population of patients with medically managed severe AS (hazard ratio 0.38, 95% confidence interval 0.15 to 0.98; p = 0.046; Table II).

Table II. Multivariable Cox regression analysis comparing adjusted hazard ratios for mortality in severe aortic stenosis.

| Parameter                          | Hazard ratio | 95% confidence interval | p-value |
|------------------------------------|--------------|-------------------------|---------|
| Older age (> 60 yr)                | 3.07         | 1.22 to 7.75            | 0.018   |
| Aortic valve area (cm²)            | 1.01         | 0.73 to 1.39            | 0.952   |
| High body mass index (≥ 27.5 kg/m²)| 0.38         | 0.15 to 0.98            | 0.046   |
Fig. 1 Kaplan-Meier survival curves show improved survival in obese patients vs. non-obese patients with medically managed severe aortic stenosis.

DISCUSSION

In the context of postoperative or post-surgical patients who had undergone valve replacements, clinical outcomes have been consistently demonstrated to be better in obese patients compared to their non-obese counterparts. These trends were also seen in other forms of cardiac surgery and intervention, including LV assist devices for heart failure. Consequent findings were also true – patients with lower BMI were found to have higher rates of periprocedural or surgical mortality and sepsis.

Of note, previous studies have consistently demonstrated better short-term (30-day) periprocedural outcomes for valve replacement in AS among obese patients. However, in terms of longer-term prognosis (one-year overall survival), the trends were less clear. A few studies have found no significant differences in prognosis between obese and non-obese
patients.\cite{23-25} However, these studies may have been limited by smaller sample sizes and consequently, may have been underpowered to demonstrate significant differences in longer-term survival between obese and non-obese patients. In fact, in a recent meta-analysis and systemic review where these studies on TAVR outcomes were pooled, it was convincingly demonstrated that higher BMI was associated with both lower short-term (30-day) mortality and better longer-term (one-year) overall survival.\cite{26}

There could be several possible reasons to explain this phenomenon, one of which is the larger body surface areas of obese patients, which may account for the better short-term periprocedural outcomes. These patients would have larger vessels that could be easier to traverse, which would in turn result in lower risks of complications and vascular injury during TAVR. In patients undergoing TAVR, smaller vessel size has been shown to be an important cause of early mortality.\cite{27}

In the present study, we examined a population of patients with severe AS that was medically managed. We adopted a more ‘stringent’ criteria for defining severe AS, where all patients met the valve area, transaortic mean pressure gradient and peak velocity criteria for severe AS (i.e. $\text{AVA}_i < 0.6 \text{ cm}^2/\text{m}^2$ and transaortic mean pressure gradient $> 40 \text{ mmHg}$ and transaortic peak velocity $> 400 \text{ cm/s}$). This population of patients with severe AS was studied because in our Asian context, a significant proportion of patients with severe AS either declined aortic valve replacement or were deemed unfit for the procedure. This population also had a significant prevalence of medical comorbidities such as ischaemic heart disease (25.0%) and chronic kidney disease (7.0%). The predicted in-hospital mortality based on EuroSCORE II was comparable in the two groups ($7.3 \pm 3.7$ vs. $7.9 \pm 5.0\%$, $p = 0.706$). Furthermore, TAVR was only introduced in our centre in 2010 and thus a significant proportion of our study population was in the pre-TAVR era. This meant that they would not have been offered TAVR if they declined surgical aortic valve replacement.
In the context of medically managed severe AS, there may have been other important protective effects of obesity. Obese patients in our study were similar in age to non-obese patients. In prior studies on the obesity paradox in patients with severe AS undergoing valve replacement, obese patients tended to be younger in age.\(^{(22,28)}\) The protective effect of obesity may thus be in part confounded by the younger age and correspondingly, better cardiac and renal function in these patients, which resulted in better clinical outcomes. However, in this study, we had adjusted for the effect of age and therefore, higher BMI remained an independent protective factor for mortality in medically managed severe AS.

Differences in nutrition may also be important in this context. This has been examined more thoroughly in patients with non-cardiac chronic diseases. The presence of weight loss often reflects malnourishment and is an indicator of severe disease, which in turn would be predictive of poorer clinical outcomes.\(^{(29)}\) Frailty with lower skeletal muscle mass and BMI may also reflect lower biological reserves, resulting in poorer clinical outcomes.\(^{(30)}\)

Furthermore, as obese patients tend to have higher prevalence of cardiovascular risk factors such as hypertension, hyperlipidaemia and diabetes mellitus, they are consequently more intensively treated with cardio-protective drugs. These patients are also more likely to be on closer follow-up with a cardiologist and compliant to guideline-based medical therapy.\(^{(31)}\) Closer monitoring and follow-up of obese patients, as well as the use of cardio-protective drugs in the obese population, may have conferred additional survival benefit.

Some authors have postulated that the adipose tissue itself may be a source of reserves for better recovery. Adipose tissue produces receptors for tumour necrosis factor alpha and helps to counteract and decrease the effect of inflammation, thereby promoting recovery.\(^{(32,33)}\) This mechanism may be important in surgical patients where wound healing is crucial, but may be less relevant in medically managed patients with severe AS and for patients undergoing less invasive procedures such as TAVR.
In contrast to the abovementioned studies and the findings of this study, a recent large study conducted in a population of patients with severe asymptomatic AS demonstrated that mortality and morbidity were higher among obese patients.\textsuperscript{(13)} However, the patients studied were all relatively young (mean age 67 ± 10 years vs. 72 ± 10 years in our study) and asymptomatic, and hence they were likely to be earlier in the course of their disease. The obesity paradox may thus only be apparent in patients who are more frail, more elderly and have more advanced disease, which was supported by findings on subgroup analyses of subsequent follow-up studies.\textsuperscript{(34)} Our study also adjusted for the effect of age and demonstrated that higher BMI was independently associated with improved survival.

Furthermore, it is important to note that the obesity paradox may be in part explained by the cross-sectional nature of the study design, which was subjected to lead-time bias. Patients were studied and compared at the time of the index echocardiographic diagnosis of severe AS, but they may individually have been at different time points along the natural history of the disease progression of AS. Patients with higher BMI may be earlier in the course of the disease, while patients later in the course with more advanced disease may have more symptoms of heart failure and cardiac cachexia that resulted in a lower BMI. This may have led to an apparent protective benefit of higher BMI on patients with severe AS, rather than obesity conferring a true survival benefit.\textsuperscript{(35)} Longitudinal prospective follow-up of obese patients with serial measurements of BMI over time and follow-up echocardiography may be important to further evaluate these trends.

This study was not without limitations. We studied a moderately sized Asian cohort of medically managed patients with severe AS. The definition of severe AS relied on parameters like aortic valve area, transaortic mean pressure gradient and peak velocity, but we did not quantify the degree of aortic valve calcification or the symptom status of the patients. However, we ensured accurate measurement of transaortic gradients in all our echocardiographic studies.
by performing multiple assessments to obtain the highest transaortic gradients, including routinely using Pedoff transducer probes. Of note, a significant proportion of our Asian cohort had paradoxical low-flow AS (31.2%), which had been similarly demonstrated in a previous study. The impact of obesity on this subgroup of patients, who may have distinct and poorer clinical outcomes, could be an important subject for future study.\(^{(36,37)}\)

Although we studied a heterogeneous group of symptomatic and asymptomatic patients, the obesity paradox was still demonstrated after adjusting for confounding factors. Establishing the time of onset of symptoms along the course of a patient’s disease and consequently comparing the duration in which these patients had been symptomatic may be useful in predicting clinical outcomes.\(^{(38)}\) We did not examine serial echocardiographic studies on follow-up for progression of AS and changes in echocardiographic profile over time. Furthermore, BMI was measured only at the time of the index echocardiography, and changes in each patient’s BMI on subsequent follow-up was not tracked. Also, obesity was quantified by means of BMI only; we did not examine or compare waist circumference or estimated body fat percentages. Abdominal obesity, which has been shown to be important in Asians, had also not been evaluated.\(^{(14)}\) The cross-sectional nature of this study also meant it was subjected to lead-time bias, where patients may have been studied at differing time points of the natural history of AS progression. Nevertheless, this study remains important, as it was both exploratory and hypothesis-generating, and the findings suggested that the obesity paradox may extend beyond periprocedural risks and complications to apply to patients with severe AS that are medically managed. Further prospective and longitudinal studies are warranted to confirm and evaluate the clinical significance of these findings.

In conclusion, this study found that obesity (BMI ≥ 27.5 kg/m\(^2\)) was associated with improved survival in an Asian population of patients with medically managed severe AS. This trend of improved survival was independent of age, AS disease severity, and was also observed
in spite of lower AVAi and higher prevalence of cardiovascular risk factors in patients with obesity.

REFERENCES

1. Dindo D, Muller MK, Weber M, Clavien PA. Obesity in general elective surgery. Lancet 2003; 361:2032-5.

2. Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083-96.

3. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002; 39:578-84.

4. Galal W, van Domburg RT, Feringa HH, et al. Relation of body mass index to outcome in patients with known or suspected coronary artery disease. Am J Cardiol 2007; 99:1485-90.

5. Roberts WC, Roberts CC, Vowels TJ, et al. Effect of body mass index on survival in patients having aortic valve replacement for aortic stenosis with or without concomitant coronary artery bypass grafting. Am J Cardiol 2011; 108:1767-71.

6. Abramowitz Y, Chakravarty T, Jilaihawi H, et al. Impact of body mass index on the outcomes following transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2016; 88:127-34.

7. Iung B, Laouénan C, Himbert D, et al; FRANCE 2 Investigators. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart 2014; 100:1016-23.

8. Clark MA, Duhay FG, Thompson AK, et al. Clinical and economic outcomes after surgical aortic valve replacement in Medicare patients. Risk Manag Healthc Policy 2012; 5:117-26.
9. Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 2006; 151:57-69.

10. Oga EA, Eseyin OR. The obesity paradox and heart failure: a systematic review of a decade of evidence. J Obes 2016; 2016:9040248.

11. Leon MB, Smith CR, Mack M, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363:1597-607.

12. Smith CR, Leon MB, Mack MJ, et al; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364:2187-98.

13. Rogge BP, Cramariuc D, Lønnebakken MT, et al. Effect of overweight and obesity on cardiovascular events in asymptomatic aortic stenosis: a SEAS substudy (Simvastatin Ezetimibe in Aortic Stenosis). J Am Coll Cardiol 2013; 62:1683-90.

14. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2014; 363:157-63.

15. Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2017; 18:254-75.

16. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16:233-70.

17. Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. Eur J Cardiothorac Surg 2012; 41:734-45.
18. Nashef SA, Roques F, Michel P, et al. European system for cardiac preoperative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16:9-13.

19. van der Boon RM, Chieffo A, Dumonteil N, et al; PRAGMATIC-Plus Researchers. Effect of body mass index on short- and long-term outcomes after transcatheter aortic valve implantation. Am J Cardiol 2013; 111:231-6.

20. Yamamoto M, Mouillet G, Oguri A, et al; FRANCE 2 Registry Investigators. Effect of body mass index on 30- and 365-day complication and survival rates of transcatheter aortic valve implantation (from the FRench Aortic National CoreValve and Edwards 2 [FRANCE 2] registry). Am J Cardiol 2013; 112:1932-7.

21. Butler J, Howser R, Portner PM, Pierson RN 3rd. Body mass index and outcomes after left ventricular assist device placement. Ann Thorac Surg 2005; 79:66-73.

22. Mano A, Fujita K, Uenomachi K, et al. Body mass index is a useful predictor of prognosis after left ventricular assist system implantation. J Heart Lung Transplant 2009; 28:428-33.

23. Koifman E, Kiramijyan S, Negi SI, et al. Body mass index association with survival in severe aortic stenosis patients undergoing transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2016; 88:118-24.

24. Kische S, D’Ancona G, Agma HU, et al. Transcatheter aortic valve implantation in obese patients: overcoming technical challenges and maintaining adequate hemodynamic performance using new generation prostheses. Int J Cardiol 2016; 220:909-13.

25. Salizzoni S, D’Onofrio A, Agrifoglio M, et al; TAVI Team. Early and mid-term outcomes of 1904 patients undergoing transcatheter balloon-expandable valve implantation in Italy: results from the Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER). Eur J Cardiothorac Surg 2016; 50:1139-48.
26. Lv W, Li S, Liao Y, et al. The ‘obesity paradox’ does exist in patients undergoing transcatheter aortic valve implantation for aortic stenosis: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2017; 25:633-42.

27. Hayashida K, Lefèvre T, Chevalier B, et al. Transfemoral aortic valve implantation new criteria to predict vascular complications. JACC Cardiovasc Interv 2011; 4:851-8.

28. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867-72.

29. Li S, Wang Z, Huang J, et al. Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: does the ‘obesity paradox’ really exist? Eur J Cardiothorac Surg 2017; 51:817-28.

30. Afilalo J, Lauck S, Kim DH, et al. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiolat 2017; 70:689-700.

31. Lancefield T, Clark DJ, Andrianopoulos N, et al; MIG (Melbourne Interventional Group) Registry. Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. JACC Cardiovasc Interv 2010; 3:660-8.

32. Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001; 38:789-95.

33. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999; 277:E971-5.

34. Rossi A, Gaibazzi N, Belletti G, et al. Obesity paradox in patients with aortic valve stenosis. Protective effect of body mass index independently of age, disease severity, treatment modality and non-cardiac comorbidities. Int J Cardiol 2014; 176:1441-3.
35. Yadav PK, Eng MH. Size does matter but is there an obesity paradox in TAVR? Catheter Cardiovasc Interv 2016; 88:125-6.

36. Ngiam JN, Tan BY, Sia CH, et al. Comparing characteristics and clinical and echocardiographic outcomes in low-flow vs normal-flow severe aortic stenosis with preserved ejection fraction in an Asian population. Echocardiography 2017; 34:638-48.

37. Muhammad N, Yap SE, Seet D, Chia BL, Poh KK. Does Oral calcium intake or body habitus relate to the degree of valvular calcification and adverse events in patients with severe aortic stenosis? Int J Cardiol 2015; 180:74-75.

38. Tay ELW, Ngiam JN, Kong WKF, Poh KK. Management of severe aortic stenosis: the Singapore and Asian perspective. Singapore Med J 2018; 59:452-4.